-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
March 2021
-
The “Holy Grail” of Lung Cancer Research: Bring the Immune System into Every Tumor
With multiple new therapies available, Prof. Johan Vansteenkiste says the search is on for biomarkers to better match patients to treatments.
-
Could the Daunting Biology of Small-Cell Lung Cancer Provide the Key to Elucidating Drug Resistance?
At ELCC 2021, Prof. Fiona Blackhall sees hope for improving patients’ poor prognoses on the horizon.
-
Cancer Clinical Trial Compensation: Undue or Long Overdue?
When compensating participants in clinical trials, the objective is to show appreciation and consideration for a patient’s time and expenses without exerting undue influence. The Office for Human Research Protections of the U.S. Department of Health and Human Services (HHS) defines undue influence as a potential consequence of an “offer of an excessive or inappropriate…
-
Increasing Understanding about the Role Biosimilar Agents Play in Everyday Practice: A Q&A with Dr. Gary Lyman (Part 2 of 2)
In September 2017, the US Food and Drug Administration (FDA) approved bevacizumab-awwb for the treatment of NSCLC, with the same indications as the tradename. Although bevacizumab-awwb is the only biosimilar agent specific to lung cancer, there are many in development, necessitating a firm understanding of the regulatory approval process and cost comparators for these agents.…
-
Fiona Blackhall: Breaking new ground in small-cell lung cancer
Liquid biopsies have also opened new perspectives in the field to which Blackhall has dedicated much of her research career. “I would like to use this award to highlight the unmet need in small-cell lung cancer, where progress has lagged behind non-small cell lung cancer in the last decade, partly because of the difficulty of…
-
Johan Vansteenkiste: A lifelong commitment to improving outcomes in thoracic oncology
Vansteenkiste leads the Respiratory Oncology Unit at University Hospitals Leuven, where he has been involved in approximately 300 lung cancer trials. He has served on the editorial boards of numerous peer-reviewed journals during his decades-long career, including a current position as associate editor for Annals of Oncology. Among other achievements, Vansteenkiste conducted benchmark-setting research into…
-
Ensuring Quality of Life During Lung Cancer Survivorship Requires a Multidisciplinary Team
Lung cancer is one of the most common cancers worldwide, with more than 2 million people diagnosed each year.1 Advances in early detection and treatment have resulted in more people surviving the disease. Nevertheless, in the United States, the overall 5-year survival rate is only 19% for all stages combined. However, in patients with localized…
-
COVID-19 and Lung Cancer: A Call for Immediate Action
The COVID-19 pandemic has had a devastating effect on lung cancer outcomes in the United Kingdom (UK). Fewer people have presented or have been referred for investigation, and those who do present have a more unfavorable stage. In October 2020, the Lung Cancer Coalition (UKLCC) published a report setting out a number of recommendations for…
-
A Clinical Trial of PD-L1 Inhibitor Durvalumab and PARP Inhibitor Olaparib for Patients With EGFR-Mutated Transformed SCLC
Discovery of targetable genomic alterations, including mutations of EGFR, have resulted in improved survival for patients with non-small cell lung cancer (NSCLC).1 Although many patients experience robust responses to EGFR-targeted therapy, acquired drug resistance is almost inevitable. Small cell lung cancer (SCLC) transformation as a mechanism of acquired resistance is reported in up to 14%…
-
Mitigating Pain in Thoracic Surgery
A middle-aged woman walks into the clinic using her right hand to hold her shirt away from her chest. “Even just my shirt brushing against my skin hurts,” she says with a grimace. The patient is now 4 months out from a thoracoscopic right upper lobectomy for early-stage NSCLC. She continues to report sharp pain…
View ILCN Archives
Provider Resources
Popular Articles